As President-elect Donald J. Trump is about enter the White House for a second term, questions about how US healthcare policy will be affected over the next four years have come under heightened scrutiny.
Similarly, with a Republican majority in the US House and Senate, it is unknown what the legislative agenda for 2025 will look like and how the nation’s public policies will evolve.
CRA Life Sciences’ Matt Majewski and Joe Black examine potential policy changes in the next four years that could benefit, harm or have a neutral impact on pharmaceutical manufacturers. It includes a look at how the first Trump administration viewed, and acted on, policy that impacted life sciences companies, and assesses what companies must to do to develop robust commercial, pricing and market access strategies that are resilient and can withstand potentially wide-reaching healthcare policy changes.
